Hemophilia A

1. Disease Information

1.1 Concise overview (current understanding)

Recent primary genetics literature provides a concise definitional statement suitable for a KB entry: “Hemophilia A (HA, OMIM#306700) is an X‑linked recessive bleeding disorder caused by the defects in the F8 gene, which encodes coagulation factor VIII (FVIII).” (li2023f8geneinversion pages 1-2)

Severity is defined by baseline FVIII activity; a 2024 expert review lists: mild 0.05–0.4 IU/mL (6%–40%), moderate 0.01–0.05 IU/mL (2%–5%), and severe <0.01 IU/mL (<1%), with spontaneous bleeding characteristic of severe disease. (gupta2024expertopinionson pages 1-2)

1.2 Key identifiers (as available from retrieved sources)

• OMIM: 306700 (Hemophilia A) (li2023f8geneinversion pages 1-2, liu2023comprehensiveanalysisof pages 1-2)
• Causal gene: F8 (Factor VIII) (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

Not available in retrieved full text evidence: MONDO ID, Orphanet ID, ICD‑10/ICD‑11 codes, MeSH ID. These are commonly available from OMIM/Orphanet/MeSH but were not present in the retrieved documents, so they are not asserted here.

1.3 Synonyms and alternative names

• Hemophilia A; HA (li2023f8geneinversion pages 1-2, gupta2024expertopinionson pages 1-2)
• Factor VIII deficiency / coagulation factor VIII deficiency (explicitly used as description/synonym) (li2023f8geneinversion pages 1-2)

1.4 Evidence provenance (patient-level vs aggregated)

The evidence in this report is derived from: * Aggregated resources: systematic reviews/meta-analyses and narrative reviews (e.g., emicizumab meta-analysis; gene therapy reviews) (prudente2024emicizumabprophylaxisin pages 6-7, deshpande2024adenoassociatedvirus–basedgene pages 1-2) * Clinical trial datasets: phase 3 GENEr8‑1 long-term follow-up and related analyses (leavitt2024efficacysafetyand pages 1-2, long2024clinicalimmunogenicityoutcomes pages 1-2) * Single-center patient series: perioperative outcomes on emicizumab (rener2023managementandoutcomes pages 1-2) * Molecular diagnostic cohorts: regional/country genetics studies (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in F8, which encodes FVIII; HA is X‑linked recessive. (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

2.2 Risk factors

Genetic risk factors

• High-impact F8 variants (e.g., deletions or nonsense variants) are noted to influence risk of developing inhibitory antibodies (inhibitors) to FVIII. A 2024 gene-therapy review states: “risk of developing inhibitory antibodies is influenced by genetic factors such as gene deletion or nonsense mutation on FVIII, as well as ethnicity.” (chernyi2024recentadvancesin pages 3-4)
• A 2024 expert review notes inhibitors can develop in up to ~30% in severe HA. (gupta2024expertopinionson pages 2-3)

Environmental/clinical risk factors

No specific environmental causal risk factor is established for congenital HA itself (genetic disorder). However, treatment exposure (repeated FVIII infusions) is tied to inhibitor formation risk and to historical infection risks in the plasma-derived era. (chernyi2024recentadvancesin pages 3-4)

2.3 Protective factors

No protective genetic variants were identified in the retrieved evidence. Clinically, achieving higher steady FVIII activity reduces spontaneous bleeding risk; Roctavian review notes FVIII levels ~12%–20% protect against spontaneous hemorrhage and joint bleeds. (samelsonjones2024roctaviangenetherapy pages 1-2)

2.4 Gene–environment interactions

Not specifically addressed in retrieved evidence for congenital HA.

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

• Bleeding diathesis ranging from trauma-related to spontaneous bleeds depending on baseline FVIII activity; spontaneous bleeding is characteristic of severe disease (<1% FVIII). (gupta2024expertopinionson pages 1-2, li2023f8geneinversion pages 1-2)
• Hemarthroses and hemophilic arthropathy are key complications; patients with inhibitors have greater morbidity including arthropathy and worse quality of life. (prudente2024emicizumabprophylaxisin pages 6-7)

3.2 Phenotype characteristics

Age of onset

Severe HA often presents early in life; an adult cohort study notes severe cases are “often diagnosed within the first two years of life,” while mild cases may be diagnosed later. (vasava2024astudyof pages 5-6)

Severity and progression

Severity is largely determined by baseline FVIII activity (mild/moderate/severe). (gupta2024expertopinionson pages 1-2) Progression is driven by recurrent bleeding (especially joints), which can lead to chronic arthropathy. (prudente2024emicizumabprophylaxisin pages 6-7)

3.3 Quality-of-life impact

A 2024 phase 3 gene-therapy follow-up reports sustained, clinically meaningful improvement in hemophilia-specific HRQoL after valoctocogene roxaparvovec at 4 years (Haemophilia-Specific Quality of Life Questionnaire total score change significant). (leavitt2024efficacysafetyand pages 1-2)

3.4 Suggested HPO terms (examples)

Because retrieved texts did not provide an explicit HPO mapping, below are suggested HPO concepts for KB normalization (not directly asserted by cited sources): * Hemarthrosis / joint bleeding: HP:0003065 (Hemarthrosis) * Abnormal bleeding: HP:0001892 (Bleeding) * Prolonged activated partial thromboplastin time: HP:0003645 (Abnormality of partial thromboplastin time) * Hemophilic arthropathy: can be represented via arthropathy terms (e.g., HP:0002758 Arthritis) + site qualifiers.

Limitation: phenotype frequency-by-HPO (percent affected) could not be robustly extracted from the retrieved evidence corpus.

4. Genetic / Molecular Information

4.1 Causal genes

• F8 (Factor VIII) is the causal gene for congenital hemophilia A. (li2023f8geneinversion pages 1-2, chernyi2024recentadvancesin pages 1-3)

Gene locus and structure: F8 is located at Xq28 and comprises 26 exons and 25 introns (~186–187 kb), per molecular diagnostic studies. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)

4.2 Pathogenic variants (variant classes and frequencies)

Hemophilia A shows extensive allelic heterogeneity (thousands of variants catalogued). (zhang2023moleculardiagnosisof pages 1-2)

Key recurrent structural variants in severe HA: * Intron 22 inversion (Inv22 / IVS22): approximately 45% of severe HA. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2) * Intron 1 inversion (Inv1 / IVS1): approximately 1–2% of severe HA. (zhang2023moleculardiagnosisof pages 1-2)

Representative abstract quote supporting Inv22 frequency: “Intron 22 inversion (Inv22) is found in about 45% of patients with severe hemophilia A.” (li2023f8geneinversion pages 1-2)

4.3 Variant detection approaches (molecular diagnostics)

A 2023 molecular study describes a standard workflow: FVIII activity (FVIII:C) by one-stage clotting assay, inhibitor titer by Bethesda assay, and genetic testing by inversion-specific PCR methods plus NGS with Sanger confirmation. (zhang2023moleculardiagnosisof pages 1-2)

4.4 Modifier genes / epigenetics

No congenital HA modifier genes or epigenetic mechanisms were identified in the retrieved evidence set.

4.5 Chromosomal abnormalities

Not a dominant mechanism in retrieved evidence beyond F8 inversions/large rearrangements. (zhang2023moleculardiagnosisof pages 1-2)

5. Environmental Information

5.1 Environmental factors

Congenital HA is genetic; no environmental causes were identified. Historical treatment-related infectious risk is documented (HIV/HCV in the 1980s era of plasma products). A 2024 review notes: “Up to 60–70% of individuals with severe hemophilia were found to have contracted HIV in the 1980s, and nearly all of them contracted hepatitis C.” (chernyi2024recentadvancesin pages 3-4)

5.2 Lifestyle factors / infectious agents

Not applicable as primary causal factors for congenital HA; infection risk pertains to past treatment-era blood product exposure. (chernyi2024recentadvancesin pages 3-4)

6. Mechanism / Pathophysiology

6.1 Causal chain (genotype → phenotype)

1. F8 pathogenic variant → reduced/absent FVIII expression or activity. (li2023f8geneinversion pages 1-2)
2. Low FVIII → impaired intrinsic pathway amplification and reduced capacity to generate stable clotting (clinically manifested as prolonged bleeding; severe disease shows spontaneous bleeds). (gupta2024expertopinionson pages 1-2, li2023f8geneinversion pages 1-2)
3. Recurrent bleeding, particularly into joints → chronic joint damage (hemophilic arthropathy) and reduced quality of life. (prudente2024emicizumabprophylaxisin pages 6-7)
4. Therapeutic FVIII exposure can induce FVIII inhibitors (alloantibodies) that neutralize infused FVIII, increasing bleeding morbidity and mortality. (prudente2024emicizumabprophylaxisin pages 6-7, gupta2024expertopinionson pages 2-3)

6.2 Key molecular/therapeutic mechanisms (2023–2024 understanding)

• Emicizumab mechanism: a bispecific antibody that “bridges the gap between activated factor IX and factor X to replace the missing activated factor VIII.” (chernyi2024recentadvancesin pages 5-6)
• Gene therapy mechanism: hepatotropic AAV gene addition to enable endogenous expression of B‑domain deleted FVIII; key limitation highlighted is declining FVIII expression over time after Roctavian. (samelsonjones2024roctaviangenetherapy pages 1-2)
• Physiologic FVIII-producing cells: liver sinusoidal endothelial cells (LSEC) are a natural FVIII source; a 2024 EMBO Mol Med study states: “Coagulation factor VIII (FVIII), the gene mutated in hemophilia A, is naturally expressed by LSEC.” (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

6.3 Suggested ontology terms

GO (Biological Process) – suggestions

• blood coagulation (GO:0007596)
• hemostasis (GO:0007599)
• regulation of thrombin generation (GO term family; specific mapping may be needed)
• immune response to foreign protein (for inhibitor formation)

CL (Cell Ontology) – suggestions

• liver sinusoidal endothelial cell (LSEC)
• hepatocyte
• macrophage / Kupffer cell
• megakaryocyte / platelet lineage (for platelet-targeted FVIII concepts)

UBERON – suggestions

• liver (UBERON:0002107)
• synovial joint (UBERON:0000978)

7. Anatomical Structures Affected

Organ/system level

• Blood / hemostasis system (primary)
• Joints (hemarthroses → arthropathy) (prudente2024emicizumabprophylaxisin pages 6-7)

Tissue/cell level

• Liver-relevant tissues for gene therapy and endogenous FVIII production include hepatocytes and LSEC (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

8. Temporal Development

• Onset: congenital; severe disease often recognized early in childhood (often within first two years), while mild disease may be diagnosed later. (vasava2024astudyof pages 5-6)
• Course: chronic lifelong without disease-modifying cure; modern prophylaxis and gene therapy aim to reduce or eliminate bleeding episodes. (leavitt2024efficacysafetyand pages 1-2)

9. Inheritance and Population

9.1 Inheritance

• X‑linked recessive inheritance (li2023f8geneinversion pages 1-2)

9.2 Epidemiology (recent statistics)

• Incidence estimates include ~1 in 5,000 male births. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)
• A 2024 immunogenicity paper states incidence as “24.6 out of 100,000 males.” (long2024clinicalimmunogenicityoutcomes pages 1-2)
• Regional prevalence example: pooled prevalence in Africa 6.82 per 100,000 persons (95% CI 5.16–8.48). (chernyi2024recentadvancesin pages 1-3)

Limitation: detailed age distribution, ethnicity-specific prevalence, and global registry-derived prevalence/incidence were not directly retrievable from the available full-text evidence.

10. Diagnostics

10.1 Clinical and laboratory testing

• Screening often begins with prolonged aPTT, while PT and platelet count can be normal; confirmatory testing measures FVIII activity. (gupta2024expertopinionson pages 2-3)
• FVIII activity measurement:
• One-stage aPTT-based clotting assay is the most common worldwide. (bowyer2023factorviiiand pages 1-2)
• Chromogenic substrate assays are used in specialized labs; one-stage vs chromogenic assays can disagree in mild HA and for some therapies, including gene therapy monitoring. (bowyer2023factorviiiand pages 1-2)

10.2 Inhibitor testing

• Inhibitor titers can be quantified using the Bethesda assay (explicitly described in 2023 molecular diagnostic work). (zhang2023moleculardiagnosisof pages 1-2)

10.3 Genetic testing

A 2023 diagnostic study lists commonly used inversion detection methods (e.g., inverse-shift PCR, long-distance PCR), and documents use of long-range PCR/multiplex PCR for Inv22/Inv1 plus NGS and Sanger confirmation for other variants. (zhang2023moleculardiagnosisof pages 1-2)

A 2024 expert review emphasizes that >3,500 pathogenic F8 variants are reported, and that NGS and Sanger sequencing improve diagnostic yield and can enable preimplantation genetic diagnosis. (gupta2024expertopinionson pages 15-16)

10.4 Differential diagnosis

Not systematically addressed for congenital HA in retrieved evidence (acquired hemophilia A and other causes of prolonged aPTT are discussed in other literature, but not part of this congenital HA evidence set).

11. Outcome / Prognosis

Modern outcomes (bleeding control)

Long-term phase 3 data show gene therapy can substantially reduce bleeding and factor usage at 4 years, with many participants experiencing zero treated bleeds in year 4. (leavitt2024efficacysafetyand pages 1-2)

Limitation: explicit life expectancy, all-cause mortality, and cause-specific mortality rates were not provided in the retrieved evidence.

12. Treatment

12.1 Standard of care: factor replacement

Regular FVIII replacement (standard or extended half-life products) remains a core prophylaxis approach; limitations include IV administration burden and inhibitor development. (gupta2024expertopinionson pages 2-3, gupta2024expertopinionson pages 1-2)

MAXO suggestions: * clotting factor replacement therapy (MAXO term family) * prophylactic treatment (MAXO:0000069; confirm exact term mapping in MAXO)

12.2 Non-factor prophylaxis: emicizumab

Evidence of effectiveness: A 2024 systematic review/meta-analysis in people with HA and inhibitors found lower treated-bleed ABR on emicizumab vs bypassing agents, with standardized mean difference −1.58 (95% CI −2.50 to −0.66; P=0.0008). (prudente2024emicizumabprophylaxisin pages 6-7)

Safety considerations: the same review notes thrombotic events/TMA have been associated with concurrent high-dose aPCC for >1 day; anti-drug antibodies were reported and emicizumab can persist for ~6 months. (prudente2024emicizumabprophylaxisin pages 6-7)

Real-world implementation: A 2023 single-center perioperative series (12 procedures in 8 adults on emicizumab) reported no major bleeds, thrombotic events, deaths, or new inhibitors, supporting feasibility of surgery with appropriate adjunct hemostasis. (rener2023managementandoutcomes pages 1-2)

MAXO suggestions: * monoclonal antibody therapy * bleeding prophylaxis

12.3 Inhibitors and immune tolerance induction (ITI)

A 2024 gene-therapy review reports ITI success is ~60%–80%, while 20%–40% of severe HA patients do not achieve tolerance, with predictors including high peak inhibitor titer and prior failed ITI. (chernyi2024recentadvancesin pages 3-4)

MAXO suggestions: * immune tolerance induction therapy

12.4 Advanced therapeutics: AAV gene therapy (Roctavian / valoctocogene roxaparvovec)

Regulatory status: Roctavian was conditionally approved in Europe (Aug 2022) and approved in the US (June 2023). (samelsonjones2024roctaviangenetherapy pages 1-2)

Efficacy at 4 years (GENEr8‑1): mean treated ABR reduced −82.6% and annualized FVIII infusion rate reduced −95.5% vs baseline; in year 4, 81/110 rollover participants had 0 treated bleeds. Week‑208 chromogenic FVIII activity mean 16.1 IU/dL, median 6.7 IU/dL. (leavitt2024efficacysafetyand pages 1-2)

Comparative effectiveness: a propensity-score comparison reports treated ABR 4.40 vs 0.85 and all-bleed ABR 5.01 vs 1.54 (FVIII prophylaxis vs valoctocogene roxaparvovec), and zero treated bleeds in 32.9% vs 82.1% (controls vs treated). (leavitt2024efficacysafetyand pages 1-2)

Immunogenicity: “No FVIII inhibitors were detected following administration of valoctocogene roxaparvovec,” and all participants developed durable anti-AAV5 antibodies; pre-existing anti-AAV5 antibodies occur in 29.7% of people with HA globally. (long2024clinicalimmunogenicityoutcomes pages 1-2)

Liver safety / monitoring: ALT elevations are common; GENEr8‑1 year‑4 data report ALT elevation as the most common adverse event (56/131 participants in year 4). (leavitt2024efficacysafetyand pages 1-2)

A 2024 Blood Advances expert guidance paper provides detailed visual guidance for liver monitoring and management of ALT elevations after Roctavian (eligibility workup, monitoring schedule, and a corticosteroid management algorithm). (mura2024liverrelatedaspectsof media 8f4fbc2d, mura2024liverrelatedaspectsof media 4d9b2f5b, mura2024liverrelatedaspectsof media 179ecf90)

13. Prevention

Genetic counseling and reproductive options

A 2024 expert review recommends genetic analysis to identify carriers and support counseling; it notes chorionic villous sampling at 11–14 weeks in carrier pregnancies and that NGS/Sanger sequencing support molecular diagnosis and preimplantation genetic diagnosis approaches. (gupta2024expertopinionson pages 15-16)

Tertiary prevention (preventing complications)

Prophylaxis to minimize bleeding is emphasized as a strategy to prevent morbidity (e.g., arthropathy), including early prophylaxis approaches. (gupta2024expertopinionson pages 2-3)

14. Other Species / Natural Disease

The retrieved evidence did not explicitly document naturally occurring hemophilia A in companion animals; it does support broader comparative models including dogs with hemophilia A used in research. (chernyi2024recentadvancesin pages 6-8)

15. Model Organisms

15.1 Common models

• Hemophilia A mouse models, including Alb‑F8*R593C strain used for gene-therapy studies. (milani2024gp64pseudotypedlentiviralvectors pages 14-15)
• Dogs with hemophilia A as large-animal translational models. (chernyi2024recentadvancesin pages 6-8)

15.2 Mechanistic relevance of cell types

A 2024 experimental gene-therapy study emphasizes LSECs as physiologic FVIII producers and demonstrates correction of hemophilia A mice by targeting FVIII expression to liver endothelium. (milani2024gp64pseudotypedlentiviralvectors pages 1-2)

Recent developments and real-world implementations (2023–2024 highlights)

1. Emicizumab continues to expand real-world use, including perioperative management with favorable outcomes in a single-center series and improved bleed prophylaxis vs bypassing agents in inhibitor populations. (prudente2024emicizumabprophylaxisin pages 6-7, rener2023managementandoutcomes pages 1-2)
2. Licensed gene therapy (Roctavian) is supported by 4‑year phase 3 outcomes demonstrating sustained reductions in ABR and factor usage, but with clinically important considerations around ALT elevations and monitoring, plus unanswered questions around FVIII expression durability declines. (samelsonjones2024roctaviangenetherapy pages 1-2, leavitt2024efficacysafetyand pages 1-2, mura2024liverrelatedaspectsof media 8f4fbc2d)

Key quantitative findings table (2023–2024)

Table: This table compiles key quantitative 2023-2024 findings for congenital Hemophilia A across epidemiology, F8 genetics, diagnostic assays, emicizumab use, and gene therapy. It is useful as a quick evidence map for populating a disease knowledge base with recent, citable data.

Notes on evidence gaps

• MONDO/Orphanet/ICD/MeSH identifiers were not present in the retrieved documents and thus are not verified here.
• Many phenotype frequencies and long-term survival/life expectancy outcomes are typically available in registries (e.g., WFH, national registries) but were not accessible in the retrieved full-text corpus.
• 2023–2024 primary trial outcome data for other non-factor agents (e.g., fitusiran, concizumab) were not present in retrievable full texts; this report therefore focuses on emicizumab and valoctocogene roxaparvovec, which were well supported.

References

1. (li2023f8geneinversion pages 1-2): Shaoying Li, Jianchun He, Liming Chu, Shuai Ren, Wenzhi He, Xiaoyan Ma, Yanchao Wang, Mincong Zhang, Lingyin Kong, Bo Liang, and Qing Li. F8 gene inversion and duplication cause no obvious hemophilia a phenotype. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1098795, doi:10.3389/fgene.2023.1098795. This article has 4 citations and is from a peer-reviewed journal.

2. (gupta2024expertopinionson pages 1-2): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

3. (liu2023comprehensiveanalysisof pages 1-2): Yingdi Liu, Dongzhi Li, Dongyi Yu, Qiaowei Liang, Guilan Chen, Fucheng Li, Lu Gao, Zhuo Li, Tiantian Xie, Le Wu, Aiping Mao, Lingqian Wu, and Desheng Liang. Comprehensive analysis of hemophilia a (cahea): towards full characterization of the f8 gene variants by long-read sequencing. Thrombosis and Haemostasis, 123:1151-1164, Jun 2023. URL: https://doi.org/10.1055/a-2107-0702, doi:10.1055/a-2107-0702. This article has 28 citations and is from a domain leading peer-reviewed journal.

4. (chernyi2024recentadvancesin pages 1-3): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

5. (prudente2024emicizumabprophylaxisin pages 6-7): Tiago Paiva Prudente, Ricardo Mesquita Camelo, Rafael Alves Guimarães, and Maria do Rosário Ferraz Roberti. Emicizumab prophylaxis in people with hemophilia a and inhibitors: a systematic review and meta-analysis. São Paulo Medical Journal, May 2024. URL: https://doi.org/10.1590/1516-3180.2023.0102.r1.20022024, doi:10.1590/1516-3180.2023.0102.r1.20022024. This article has 1 citations.

6. (deshpande2024adenoassociatedvirus–basedgene pages 1-2): Saarang R. Deshpande, Keerthy Joseph, Jiayi Tong, Yong Chen, Allyson Pishko, and Adam Cuker. Adeno-associated virus–based gene therapy for hemophilia a and b: a systematic review and meta-analysis. Blood Advances, 8:5957-5974, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024014111, doi:10.1182/bloodadvances.2024014111. This article has 27 citations and is from a peer-reviewed journal.

7. (leavitt2024efficacysafetyand pages 1-2): Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V. Quon, Adam Giermasz, Maria Fernanda López Fernández, Gili Kenet, Gillian Lowe, Nigel S. Key, Carolyn M. Millar, Steven W. Pipe, Bella Madan, Sheng-Chieh Chou, Robert Klamroth, Jane Mason, Hervé Chambost, Flora Peyvandi, Elaine Majerus, Dominic Pepperell, Christine Rivat, Hua Yu, Tara M. Robinson, and Margareth C. Ozelo. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia a in the phase 3 gener8-1 trial. Research and Practice in Thrombosis and Haemostasis, 8:102615, Nov 2024. URL: https://doi.org/10.1016/j.rpth.2024.102615, doi:10.1016/j.rpth.2024.102615. This article has 37 citations and is from a peer-reviewed journal.

8. (long2024clinicalimmunogenicityoutcomes pages 1-2): Brian R. Long, Tara M. Robinson, Jonathan R.S. Day, Hua Yu, Kelly Lau, Urooj Imtiaz, Kathryn S. Patton, Greg de Hart, Joshua Henshaw, Suresh Agarwal, Christian Vettermann, Stephen J. Zoog, and Soumi Gupta. Clinical immunogenicity outcomes from gener8-1, a phase 3 study of valoctocogene roxaparvovec, an aav5-vectored gene therapy for hemophilia a. Molecular Therapy, 32:2052-2063, Jul 2024. URL: https://doi.org/10.1016/j.ymthe.2024.05.033, doi:10.1016/j.ymthe.2024.05.033. This article has 27 citations and is from a highest quality peer-reviewed journal.

9. (rener2023managementandoutcomes pages 1-2): Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, and Irena Preložnik Zupan. Management and outcomes of invasive procedures in individuals with hemophilia a on emicizumab prophylaxis: a single center experience. Hematology Reports, 15:597-607, Nov 2023. URL: https://doi.org/10.3390/hematolrep15040062, doi:10.3390/hematolrep15040062. This article has 4 citations.

10. (zhang2023moleculardiagnosisof pages 1-2): Xialin Zhang, Kun Chen, Sicheng Bian, Gang Wang, Xiuyu Qin, Ruijuan Zhang, and Linhua Yang. Molecular diagnosis of hemophilia a and pathogenesis of novel f8 variants in shanxi, china. Global Medical Genetics, 10:247-262, Sep 2023. URL: https://doi.org/10.1055/s-0043-1774322, doi:10.1055/s-0043-1774322. This article has 3 citations.

11. (chernyi2024recentadvancesin pages 3-4): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

12. (gupta2024expertopinionson pages 2-3): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

13. (samelsonjones2024roctaviangenetherapy pages 1-2): Benjamin J. Samelson-Jones, Juliana C. Small, and Lindsey A. George. Roctavian gene therapy for hemophilia a. Blood Advances, 8:5179-5189, Oct 2024. URL: https://doi.org/10.1182/bloodadvances.2023011847, doi:10.1182/bloodadvances.2023011847. This article has 38 citations and is from a peer-reviewed journal.

14. (vasava2024astudyof pages 5-6): Renuka Vasava, Minal Shastri, Vaishnavi M Rathod, Gayatri Laha, Vaishnovi Vaishnovi, Nipakumari J Patel, Rajani Deshagoni, Prerna Singh, Nandan Joshi, and Darshankumar M Raval. A study of clinical profile and treatment in adult hemophilia patients with special reference to the inhibitor levels. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54663, doi:10.7759/cureus.54663. This article has 2 citations.

15. (chernyi2024recentadvancesin pages 5-6): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

16. (milani2024gp64pseudotypedlentiviralvectors pages 1-2): Michela Milani, Cesare Canepari, S. Assanelli, Simone Merlin, Ester Borroni, Francesco Starinieri, Mauro Biffi, Fabio Russo, Anna Fabiano, Desirèe Zambroni, Andrea Annoni, L. Naldini, Antonia Follenzi, and Alessio Cantore. Gp64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia a mice. EMBO Molecular Medicine, 16:1427-1450, Apr 2024. URL: https://doi.org/10.1038/s44321-024-00072-8, doi:10.1038/s44321-024-00072-8. This article has 17 citations and is from a highest quality peer-reviewed journal.

17. (bowyer2023factorviiiand pages 1-2): Annette E. Bowyer and Robert C. Gosselin. Factor viii and factor ix activity measurements for hemophilia diagnosis and related treatments. Seminars in Thrombosis and Hemostasis, 49:609-620, Dec 2023. URL: https://doi.org/10.1055/s-0042-1758870, doi:10.1055/s-0042-1758870. This article has 42 citations and is from a peer-reviewed journal.

18. (gupta2024expertopinionson pages 15-16): Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M. J. John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, and Vijay Shah. Expert opinions on the management of hemophilia a in india: the role of emicizumab. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.c172, doi:10.7759/cureus.c172. This article has 13 citations.

19. (mura2024liverrelatedaspectsof media 8f4fbc2d): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

20. (mura2024liverrelatedaspectsof media 4d9b2f5b): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

21. (mura2024liverrelatedaspectsof media 179ecf90): Vincenzo La Mura, Vincenzo Cardinale, Raimondo De Cristofaro, Adriano De Santis, Giovanni Di Minno, Luca Fabris, Fabio Marra, Filomena Morisco, Flora Peyvandi, Maurizio Pompili, Cristina Santoro, Ezio Zanon, and Giancarlo Castaman. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia a: expert guidance for clinical practice. Blood Advances, 8:5725-5734, Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024013750, doi:10.1182/bloodadvances.2024013750. This article has 11 citations and is from a peer-reviewed journal.

22. (chernyi2024recentadvancesin pages 6-8): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 40 citations.

23. (milani2024gp64pseudotypedlentiviralvectors pages 14-15): Michela Milani, Cesare Canepari, S. Assanelli, Simone Merlin, Ester Borroni, Francesco Starinieri, Mauro Biffi, Fabio Russo, Anna Fabiano, Desirèe Zambroni, Andrea Annoni, L. Naldini, Antonia Follenzi, and Alessio Cantore. Gp64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia a mice. EMBO Molecular Medicine, 16:1427-1450, Apr 2024. URL: https://doi.org/10.1038/s44321-024-00072-8, doi:10.1038/s44321-024-00072-8. This article has 17 citations and is from a highest quality peer-reviewed journal.